Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Leonard

Showing results (521-530 of 686) with videos related to

Pageof 69
Sort By:
British Journal of Haematology|February 7, 2019
Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance)Cara A Rosenbaum, Sin-Ho Jung, Brandelyn Pitcher, et al.
Journal of the Neurological Sciences|October 11, 2005
Exploiting genotypic differences to identify genes important for EAE developmentScott A Jelinsky, Joy S Miyashiro, Kathryn A Saraf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2005
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomasRichard I Fisher, Mark S Kaminski, Richard L Wahl, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2010
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategiesRebecca L Elstrom, Peter Martin, Katya Ostrow, et al.
Elife|September 20, 2022
Distance estimation from monocular cues in an ethological visuomotor taskPhilip R L Parker, Elliott T T Abe, Natalie T Beatie, et al.
Blood Advances|September 8, 2023
Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphomaSamuel Yamshon, Gui Zhen Chen, Caitlin Gribbin, et al.
ACS Synthetic Biology|April 3, 2018
Genetic Engineering of Bee Gut Microbiome Bacteria with a Toolkit for Modular Assembly of Broad-Host-Range PlasmidsSean P Leonard, Jiri Perutka, J Elijah Powell, et al.
The Journal of Allergy and Clinical Immunology|February 8, 2005
TH1-mediated airway hyperresponsiveness independent of neutrophilic inflammationJunqing Cui, Stephen Pazdziorko, Joy S Miyashiro, et al.
Blood|November 5, 1997
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma productionJ P Leonard, M L Sherman, G L Fisher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance)P Martin, S-H Jung, B Pitcher, et al.
Pageof 69

Showing results (521-530 of 686) with videos related to

Sort By:
Pageof 69
British Journal of Haematology|February 7, 2019
Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance)Cara A Rosenbaum, Sin-Ho Jung, Brandelyn Pitcher, et al.
Journal of the Neurological Sciences|October 11, 2005
Exploiting genotypic differences to identify genes important for EAE developmentScott A Jelinsky, Joy S Miyashiro, Kathryn A Saraf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2005
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomasRichard I Fisher, Mark S Kaminski, Richard L Wahl, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2010
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategiesRebecca L Elstrom, Peter Martin, Katya Ostrow, et al.
Elife|September 20, 2022
Distance estimation from monocular cues in an ethological visuomotor taskPhilip R L Parker, Elliott T T Abe, Natalie T Beatie, et al.
Blood Advances|September 8, 2023
Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphomaSamuel Yamshon, Gui Zhen Chen, Caitlin Gribbin, et al.
ACS Synthetic Biology|April 3, 2018
Genetic Engineering of Bee Gut Microbiome Bacteria with a Toolkit for Modular Assembly of Broad-Host-Range PlasmidsSean P Leonard, Jiri Perutka, J Elijah Powell, et al.
The Journal of Allergy and Clinical Immunology|February 8, 2005
TH1-mediated airway hyperresponsiveness independent of neutrophilic inflammationJunqing Cui, Stephen Pazdziorko, Joy S Miyashiro, et al.
Blood|November 5, 1997
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma productionJ P Leonard, M L Sherman, G L Fisher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance)P Martin, S-H Jung, B Pitcher, et al.
Pageof 69